Retaspimycin: Phase II started

Infinity began an open-label, international Phase II trial to evaluate Herceptin trastuzumabplus 300 mg/kg intravenous IPI-504 given twice weekly for 2 weeks as part of a 3-week cycle in 46 patients ...